Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol Myers Squibb receives Health Canada approval for Atripla

Bristol Myers Squibb receives Health Canada approval for Atripla

18th October 2007

Bristol-Myers Squibb (BMS) and Gilead Sciences have received approval from Health Canada for their Atripla 600mg and 300mg.

Indicated for the treatment of HIV-1 infection in adults, Atripla is now the first once-daily single tablet regimen to be approved in Canada for either stand-alone therapy or in combination with other antiretrovirals.

Mark Wainberg, director of the McGill AIDS Centre, underlined the importance of Atripla in the fight against HIV and Aids.

“I commend the companies involved for joining forces to make Atripla, the first complete three-drug regimen in a single once-daily pill.”

Atripla is developed through a joint venture between the two pharmaceutical companies and comprises of Sustiva which is manufactured by BMS and Truvada which is manufactured by Gilead Sciences

Health Canada’s decision comes off the back of US Food and Drug Administration approval in July 2006 which has seen Atripla become the most prescribed treatment regimen for patients starting HIV therapy in America.

Earlier this week, BMS received approval by the FDA for Ixempra, a monotherapy for the treatment of patients with metastatic or locally advanced breast cancer.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.